New pricing models being used by The Institute for Clinical and Economic Review to evaluate COVID-19 treatments may put drug sponsors on the defensive just as industry is hoping its works to combat the crisis could burnish its public image. ICER employed the new models because of the unique nature of the global pandemic, and they appear likely to result in lower pricing benchmarks for drugs than the group's typical analysis framework would.
ICER’s “Alternative Pricing Models for Remdesivir and Other Potential Treatments for COVID-19,” published on 1 May, describes its current...







